Journal Mobile Options
Table of Contents
Vol. 10, No. 1-4, 2012
Issue release date: April 2012

Differential Diagnosis in Alzheimer’s Disease and Dementia with Lewy Bodies via VMAT2 and Amyloid Imaging

Villemagne V.L. · Okamura N. · Pejoska S. · Drago J. · Mulligan R.S. · Chételat G. · O’Keefe G. · Jones G. · Kung H.F. · Pontecorvo M. · Masters C.L. · Skovronsky D.M. · Rowe C.C.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: The noninvasive evaluation of nigrostriatal dopaminergic integrity by PET can provide useful information for the differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD). Objectives: To evaluate the diagnostic potential of imaging striatal monoaminergic terminal integrity with the novel vesicular monoamine transporter type 2 (VMAT2) radioligand [18F]AV-133 and PET to distinguish DLB from AD. Methods: Fifty participants [9 DLB, 11 AD, 20 Parkinson’s disease (PD) and 10 healthy age-matched control subjects (HC)] underwent [18F]AV-133 PET studies. Additionally, 20 participants underwent amyloid imaging PET scans with either [11C]PiB or 18F-florbetaben. VMAT2 density was calculated through normalized tissue uptake value ratios (RT) at 120–140 min after injection using the primary visual or the cerebellar cortex as reference region. Comparison of the RT for [18F]AV-133 was done between the different clinical diagnostic groups. Results: Significantly lower striatal VMAT2 densities were observed in DLB and PD when compared to AD and HC, especially in the posterior putamen. In contrast to PD and DLB, no reductions were observed in AD patients when compared to HC. Conclusions: [18F]AV-133 allows assessment of nigrostriatal degeneration in Lewy body diseases. In contrast to amyloid imaging, VMAT2 imaging with [18F]AV-133 can robustly detect reductions of dopaminergic nigrostriatal afferents in DLB patients, assisting in the differential diagnosis from AD.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, et al: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863–1872.
  2. McKeith IG, Mosimann UP: Dementia with Lewy bodies and Parkinson’s disease. Parkinsonism Relat Disord 2004;10(suppl 1): S15–S18.

    External Resources

  3. Kemp PM, Holmes C: Imaging in dementia with Lewy bodies: a review. Nucl Med Commun 2007;28:511–519.
  4. Koeppe RA, Gilman S, Joshi A, Liu S, Little R, Junck L, Heumann M, et al: 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. J Nucl Med 2005;46:936–944.
  5. Kung MP, Hou C, Goswami R, Ponde DE, Kilbourn MR, Kung HF: Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters. Nucl Med Biol 2007;34:239–246.
  6. Hefti FF, Kung HF, Kilbourn MR, Carpenter AP, Clark CM, Skovronsky DM: 18F-AV-133: a selective VMAT2-binding radiopharmaceutical for PET imaging. PET Clin 2010;5:75–82.

    External Resources

  7. Okamura N, Villemagne VL, Drago J, Pejoska S, Dhamija RK, Mulligan RS, Ellis JR, et al: In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J Nucl Med 2010;51:223–228.
  8. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, et al: Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68:1718–1725.
  9. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O’Keefe G, Tochon-Danguy H, et al: Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7:129–135.
  10. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, Villemagne VL, et al: Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008;79:1331–1338.
  11. Frey KA, Koeppe RA, Kilbourn MR: Imaging the vesicular monoamine transporter. Adv Neurol 2001;86:237–247.
  12. Suzuki M, Desmond TJ, Albin RL, Frey KA: Striatal monoaminergic terminals in Lewy body and Alzheimer’s dementias. Ann Neurol 2002;51:767–771.
  13. Miller GW, Erickson JD, Perez JT, Penland SN, Mash DC, Rye DB, Levey AI: Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson’s disease. Exp Neurol 1999;156:138–148.
  14. Koeppe RA, Frey KA, Kuhl DE, Kilbourn MR: Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine. J Cereb Blood Flow Metab 1999;19:1376–1384.
  15. Martin WR, Wieler M, Stoessl AJ, Schulzer M: Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson’s disease. Ann Neurol 2008;63:388–394.

    External Resources

  16. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L: Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer’s disease and Parkinson’s disease. Proc Natl Acad Sci USA 2001;98:12245–12250.
  17. Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE: Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 2001;16:622–630.
  18. Iranzo A, Lomena F, Stockner H, Valldeoriola F, Vilaseca I, Salamero M, Molinuevo JL, et al: Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. Lancet Neurol 2010;9:1070–1077.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50